Skip to content
HowShorted

TG THERAPEUTICS, INC. short interest in 2025

In 2025, TG THERAPEUTICS, INC.'s disclosed short interest ran from 17.75% of shares outstanding on 15 Jan 2025 to 16.11% on 31 Dec 2025, a change of -1.64 percentage points. The year's high was 17.75% on 15 Jan 2025 and its low 14.37% on 15 May 2025, averaging 15.61% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.26 days on 31 Dec 2025. Full history: TG THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for TG THERAPEUTICS, INC. in 2025

2025 in figures

Start of year
17.75% (15 Jan 2025)
End of year
16.11% (31 Dec 2025)
Change
-1.64 pp
High
17.75% (15 Jan 2025)
Low
14.37% (15 May 2025)
Average
15.61%
Highest days to cover
18.26 (31 Dec 2025)
SEC filings marked
8

Every report in 2025

TG THERAPEUTICS, INC. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202517.75%8.54
31 Jan 202517.27%12.49
14 Feb 202516.54%18.23
28 Feb 202516.52%14.41
14 Mar 202516.70%5.3610-K filed, results (8-K)
31 Mar 202515.85%10.61
15 Apr 202514.99%7.05
30 Apr 202514.72%10.51
15 May 202514.37%5.72results (8-K), 10-Q filed
30 May 202515.01%15.63
13 Jun 202515.09%12.78
30 Jun 202515.32%14.50
15 Jul 202515.39%16.85
31 Jul 202514.92%14.64
15 Aug 202514.84%6.22results (8-K), 10-Q filed
29 Aug 202515.45%13.34
15 Sep 202515.50%10.83
30 Sep 202514.88%11.57
15 Oct 202515.01%15.41
31 Oct 202514.85%14.23
14 Nov 202515.89%10.42results (8-K), 10-Q filed
28 Nov 202515.81%13.49
15 Dec 202515.82%17.56
31 Dec 202516.11%18.26

See also: TG THERAPEUTICS, INC.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.